Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?

The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.

More from Archive

More from Pink Sheet